We describe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T cell
responses, soluble markers of inflammation, and antibody levels and neutralization capacity …

Disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
ranges from mild illness to severe respiratory disease and death. In this study, we …

Despite RT-PCR confirmed COVID-19, specific antibodies to SARS-CoV-2 spike are
undetectable in serum in approximately 10% of convalescent patients after mild disease …

A subset of COVID-19 patients exhibit post-acute sequelae of COVID-19 (PASC), but little is
known about the immune signatures associated with these syndromes. We investigated …

SARS-CoV-2 has been identified as the causative agent of a global outbreak of respiratory
tract disease (COVID-19). In some patients, the infection results in moderate to severe acute …

As of January 2022, at least 60 million individuals are estimated to develop post-acute
sequelae of SARS-CoV-2 (PASC) after infection with severe acute respiratory syndrome …

Background Characterizing the longevity and quality of cellular immune responses to severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enhances understanding of …

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is the causative agent of
the current coronavirus disease 2019 (COVID‐19) pandemic. Understanding the immune …

Cellular and humoral immunity to SARS-CoV-2 is critical to control primary infection and
correlates with severity of disease. The role of SARS-CoV-2-specific T cell immunity, its …

Objectives This study aimed to explore the severe acute respiratory syndrome coronavirus 2
(SARS‐CoV‐2)‐specific humoral responses and T‐cell responses in patients who have …